Akışa dön
65/100 Bearish 15.07.2026 · 14:38 Finrend AI ⏱ 1 dk 👁 3 TR

J&J's Medtech Revenue Misses Expectations, Overshadowing Profit Growth

Johnson & Johnson (J&J) exceeded profit expectations in its fourth-quarter financial results, but its medical technology (medtech) segment's revenue performance disappointed. The company's medtech unit fell short of analysts' sales forecasts, overshadowing overall earnings growth. This drew investors' attention to weakness in one of the company's key growth areas. J&J's total revenue slightly surpassed expectations, driven by strong performance in pharmaceuticals and consumer health products, but the medtech division lagged behind targets due to declining demand for surgical and orthopedic products. The company attributed challenges in this segment to inflation and supply chain issues. Analysts noted that despite J&J's growth potential in medtech, short-term margin pressures and increasing competition are concerns. The company's shares experienced a slight decline following the news, as investors closely monitor the pace of recovery in the medtech unit. J&J management stated that for 2024, they aim to revitalize growth in the medtech segment through innovation and new product launches. However, current macroeconomic conditions and a slowdown in healthcare spending may complicate achieving these goals. This is not investment advice.

📊 GOOGL — Piyasa Yorumu

▼ down · 60%

Although GOOGL shares have risen 5% in the last 24 hours, the RSI has entered overbought territory at 74. This increases the likelihood of a short-term correction or profit-taking. While the news headline does not directly concern Google, it can be considered a healthcare sector story that may negatively affect overall market sentiment. The overbought signal from technical indicators and the potential for weakening momentum support a short-term downward move. However, since the direct impact of the news is limited, I forecast a downside move with moderate confidence.

RSI 14
74.3
MACD
2.57
24h Δ
5.00%

📊 JNJ — Piyasa Yorumu

▼ down · 70%

The news headline indicates that Johnson & Johnson's medtech revenue fell short of expectations, overshadowing profit growth. This negative development could add further pressure on the stock, which is already technically weak. Despite the RSI being in oversold territory at 27.7, the MACD remains below the signal line and in negative territory. The price is trading below both the 20-day and 50-day moving averages, confirming a short-term downtrend. The 2.9% decline over the past 24 hours suggests continued selling pressure. While the downtrend is likely to persist in the near term, oversold conditions could trigger some buying interest.

RSI 14
27.7
MACD
-2.03
24h Δ
-2.89%
Canlı Grafikler

🔗 İlgili haberler

🧬 Buna benzer

AI tarafından yeniden derlenmiştir. Yatırım tavsiyesi değildir.